Dolutegravir/Rilpivirine
Brand name: Juluca
Rank #117 of 500 drugs by total cost
$148.9M
Total Cost
41,081
Total Claims
$148.9M
Total Cost
1,234
Prescribers
$3,624
Cost per Claim
1,334
Beneficiaries
42,777
30-Day Fills
$121K
Avg Cost/Provider
33
Avg Claims/Provider
About Dolutegravir/Rilpivirine
Dolutegravir/Rilpivirine (sold as Juluca) was prescribed 41,081 times by 1,234 Medicare Part D providers in 2023, costing the program $148.9M. At $3,624 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 114 | Teriparatide (Forteo) | $153.9M | 38,259 |
| 115 | Ixekizumab (Taltz Autoinjector) | $149.8M | 19,972 |
| 116 | Sofosbuvir/Velpatasvir (Epclusa) | $149.4M | 6,544 |
| 117 | Dolutegravir/Rilpivirine (Juluca) | $148.9M | 41,081 |
| 118 | Lisinopril (Lisinopril) | $145.8M | 15,744,768 |
| 119 | Ofatumumab (Kesimpta Pen) | $144.6M | 14,774 |
| 120 | Emtricitab/Rilpiviri/Tenof Ala (Odefsey) | $144.1M | 37,441 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology